A Pharmacokinetic Study of 5-FU/Leucovorin and Alpha-Interferon in Advanced Cancer

Author: Larsson Per-Anders   Glimelius Bengt   Jeppsson Bengt   Jönsson Per-Ebbe   Malmberg Martin   Gustavsson Bengt   Carlsson Göran   Svedberg Margit  

Publisher: Informa Healthcare

ISSN: 0284-186X

Source: Acta Oncologica, Vol.39, Iss.1, 2000-04, pp. : 59-63

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

The present study was designed to study 5-FU pharmacokinetics after interferon. Weekly bolus 5-FU (500 mg/m2), immediately followed by leucovorin (60 mg/m2) was given in 14 weekly cycles to 55 gastrointestinal and breast cancer patients. Interferon-α was given on days 2, 4 and 6, starting from cycle 2 at a dose of 0.5 million units (MU) and stepwise increased to 12 MU in cycles 12 and 13. Five patients could not tolerate the treatment even at the lowest dose of interferon and 22 patients were unavailable for the pharmacokinetic analysis because of dose reductions of 5-FU. Five patients were able to follow the protocol to 12 MU, whereas most patients were unable to continue owing to toxicity. 5-FU pharmacokinetics was analysed every second cycle. Peak concentration and AUC were increased after 12 MU of interferon, but no other significant influence of interferon on pharmacokinetic parameters of 5-FU was observed.

Related content